Spectral Diagnostics Inc. Board of Directors

Board of Directors
R. Ian Lennox Director Mr. Lennox is Chairman of Ricerca Biosciences LLC and an experienced board member and business executive in the life sciences industry. He has served as President & CEO, MDS Pharmaceutical & Biotechnology Markets, President & CEO, MDS Drug Discovery & Development Sector, President & CEO, Phoenix International Life Sciences, CEO, Drug Royalty Corporation and as the President & CEO of Monsanto Canada. He currently serves as a director of MSBi Ventures, MERGE Healthcare and the Company. His previous board experience includes serving as Chairman of Stressgen Biotechnologies Corporation, Labopharm Inc. and Drug Royalty Corp. and as a Director of GenSci Regeneration Inc., Marsulex Inc., Hemosol Inc. and MDS Capital (Venture) Corp. Mr. Lennox received an Honours B. Sc. degree in physiology and pharmacology and an M.B.A. from The University of Western Ontario and has completed the executive management program in finance at the Columbia School of Business.

Paul Walker, M.D., Ph.D., F.R.C.S.C Director President & Chief Executive Officer Spectral Diagnostics, Inc. Dr. Walker left the position of COO of the Toronto General Hospital to join Spectral Diagnostics Inc. as President and CEO in April 2001. Previously, Dr. Walker was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto. Dr. Walker received his M.D from the University of Western Ontario, his Ph.D from the Salgrenska University of Göteborg Sweden, and is the author of over 100 scientific publications. Dr. Walker is a graduate of the Advanced Management Program from Harvard School of Business.

Anthony Bihl Director Mr. Bihl is an experienced executive with more than 25 years in leadership of global healthcare businesses, including a broad base of operational and executive positions in large and medium multinational healthcare firms. He was CEO of Siemens Medical Solutions Diagnostics in 2007, responsible for this new worldwide business unit, the combination of the former Bayer Diagnostics and Diagnostic Products Corporation. Prior to that Mr. Bihl served in senior leadership roles at Bayer Healthcare Diagnostics from 2000-2006, including Senior VP of Finance and Administration, and was President from 2004-2006, responsible for all aspects of this worldwide business Division. Mr. Bihl previously gained extensive operational experience though 20 years at E.I. DuPont Inc., concluding as a Plant Manager for medical instrument manufacturing. He received a Bachelors’ Degree in Business Administration from Pennsylvania State University, and is a member of the Board of Directors for Adnavance Technologies Inc.

Henry G. Friesen, C.C., M.D., F.R.S.C., F.R.C.P. Director Dr. Friesen obtained his M.D. degree from the University of Manitoba. He is a Fellow of the Royal Society of Canada and of the College of Physicians and Surgeons of Canada (FRCP). He began his career in research in endocrinology at the New England Medical Center, Boston. His academic appointments include McGill University from 1965 to 1973 and the University of Manitoba 1973 to 1992, where he served as Professor and Head of the Department of Physiology and remains a Distinguished Professor Emeritus. Among his many honours and achievements, Dr. Friesen was President of the Medical Research of Canada, the visionary who conceived the Canadian Institutes of Health Research and the founding Chair of Genome Canada, a non-profit organization supporting genomics for the benefit of Canadian science and technology.

Mr. Guillermo Herrera Director Mr. Herrera is a seasoned global healthcare executive with more than 25 years of experience. Mr. Herrera spent 24 years at Abbott Laboratories, most recently serving as Senior Vice President, International Operations and President of Abbott International. In this role, Mr. Herrera was accountable for International Commercial Operations including sales and marketing of pharmaceutical, nutritional and hospital products in markets outside the US. In 2004, Mr. Herrera joined Rosetta Partners LLC as the Partner and Principal in charge of the private equity division. Mr. Herrera received a BA in Industrial Economics from the Universidad del Valle, Colombia, and his MBA from the Kellogg Graduate School of Management at Northwestern University.

Edward E. McCormack Director Mr. McCormack is an independent business consultant. From 1987 to 1999 he was the Senior Vice-President, Chief Financial Officer and a Director of Novopharm Limited, one of North America’s largest generic pharmaceutical product manufacturers. Mr. McCormack was also the President of Almad Investments Limited and Beaver Power Corporation, investment companies associated with Novopharm Limited. Mr. McCormack’s financial background includes specific experience in private placements, bank financing and restructuring, acquisitions and divestitures. He is a member of the Ontario Institute of Chartered Accountants and the former Chairman of the Board and Chairman of the Audit Committee at Hemosol Corp.

G.E. Peterson Director Mr. Peterson is a partner with the law firm of Carlyle ● Peterson Lawyers LLP. He practises corporate law with an emphasis on development stage biotechnology companies. Mr. Peterson has served as a director and secretary of a number of public and large private companies, a lecturer at the University of Western Ontario Law School and is a director of the Canadian Olympic Committee. He received his law degree and M.B.A. from the University of Western Ontario and a B.B.A. (Honours) from Simon Fraser University.